Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
Portfolio Pulse from
Fulgent Genetics is considered undervalued with a Price/Book ratio of 0.47x and a Net Current Assets Value of 0.72x. The CFO's recent purchase of $1.5 million in shares indicates confidence, but the company is currently not profitable.
March 20, 2025 | 10:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fulgent Genetics is trading at a low Price/Book ratio of 0.47x and a Net Current Assets Value of 0.72x, indicating undervaluation. The CFO's recent $1.5 million share purchase suggests confidence in the company's future, despite current lack of profitability.
The low Price/Book ratio and Net Current Assets Value suggest that the stock is undervalued. The CFO's significant share purchase is a positive signal, indicating insider confidence. However, the company's current lack of profitability tempers the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100